Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib—a biological or synthetic target specific) in patients hospitalized with COVID-19

Barbosa, A. N., Silvinato, A., Bacha, H., Floriano, I., Tanni, S., & Bernardo, W. (2022). Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib—a biological or synthetic target specific) in patients hospitalized with COVID-19. Revista Da Associacao Medica Brasileira, 68(1), 3–8. https://doi.org/10.1590/1806-9282.2022D681